<SEC-DOCUMENT>0001279569-18-000095.txt : 20180117
<SEC-HEADER>0001279569-18-000095.hdr.sgml : 20180117
<ACCEPTANCE-DATETIME>20180117071042
ACCESSION NUMBER:		0001279569-18-000095
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180116
FILED AS OF DATE:		20180117
DATE AS OF CHANGE:		20180117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		18529755

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of January 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS INCLUDED AS PART OF THIS
REPORT </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit(s)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">News Release Dated January 16, 2018: ESSA Expects 180-Day Extension to Regain Compliance with the NASDAQ Bid Price Rule</A></FONT></P>


</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    January 16, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JANUARY 16, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><IMG SRC="image_001.jpg" ALT="ESSA Logo (CNW Group|ESSA Pharma Inc)" STYLE="height: 69px; width: 184px"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>ESSA expects 180-day extension to regain compliance with
the Nasdaq Bid Price Rule</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">HOUSTON and VANCOUVER, Jan. 16, 2018 /CNW/ - ESSA Pharma Inc.
(TSXV: EPI; Nasdaq: EPIX) (&quot;<B>ESSA</B>&quot; or the &quot;<B>Company</B>&quot;) announced today that it expects to receive
a letter (the &quot;Nasdaq Notice&quot;) from the Nasdaq Stock Market (&quot;Nasdaq&quot;), granting the Company an additional
180-day period, or until approximately July 16, 2018, to regain compliance with Nasdaq's minimum US$1.00 bid price per share rule
(the &quot;Bid Price Rule&quot;) for continued listing on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The Company expects the Nasdaq Notice to indicate that while
the Company has not regained compliance with the Bid Price Rule, it will be eligible for an additional 180-day grace period, until
approximately July 16, 2018 (the &quot;Expiration Date&quot;), to regain compliance with the Bid Price Rule. Nasdaq's determination
will be based on the Company having met the continued listing requirement for market value of publicly held shares and all other
applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the Bid Price Rule, and the Company's
written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock
split, if necessary.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Under the Company's recent brokered equity offering, which
closed in two tranches on January 9, 2018 and January 16, 2018, respectively, and concurrent non-brokered private placement, which
closed on January 9, 2018, the Company has raised total gross proceeds of approximately US$26 million. As a result, the Company's
pro forma shareholders' equity is approximately US$17.5 million as of the date hereof, in comparison to the Company's shareholders'
deficiency of approximately US$(4.5) million as of September 30, 2017. Accordingly, the Company believes it has regained compliance
with the Nasdaq's continued listing &quot;equity&quot; standard and expects to receive an additional letter from the Nasdaq indicating
that the Company has resolved the previously announced Nasdaq notice of market value deficiency letter dated July 20, 2017.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About ESSA Pharma Inc. </B><BR>
ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castrate resistant
prostate cancer (&quot;CRPC&quot;) in patients whose disease is progressing despite treatment with current therapies. ESSA believes
that its proprietary compounds can significantly expand the interval of time in which patients suffering from CRPC can benefit
from hormone- based therapies, by disrupting the androgen receptor (&quot;AR&quot;) signaling pathway that drives prostate cancer
growth, and by preventing AR transcriptional activity by binding selectively to the N-terminal domain (&quot;NTD&quot;) of the
AR.&nbsp; A functional NTD is essential for transactivation of the AR. In preclinical studies, blocking the NTD has demonstrated
the capability to overcome the known AR-dependent mechanisms of CRPC.&nbsp; ESSA was founded in 2009.&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Forward-Looking Statement Disclaimer</B><BR>
<I>This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the
meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, statements about the Company's expectations
to (i) receive an additional 180 day period to comply with the Nasdaq's Bid Price Rule and (ii) receive a notifification from the
Nasdaq that the Company has resolved the previously announced Nasdaq notice of market value deficiency letter dated July 20, 2017.&nbsp;&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking statements and information are subject
to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which
may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby.
Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are
inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and
contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory
approvals, including the Nasdaq Notice; and (iv) general business, market and economic conditions. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated December 11, 2017
under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile on the SEDAR website at www.sedar.com,
ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements
are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation
to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may
be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty
to forward-looking statements. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Neither the TSXV nor its Regulation Service Provider (as
that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">View original content with multimedia: http://www.newswire.ca/en/releases/archive/January2018/16/c2137.html</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">%CIK: 0001633932</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>David S. Wood, Chief Financial Officer,
Tel: (778) 331-0962</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CNW 21:40e 16-JAN-18</P>



<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !# *T# 2(  A$! Q$!_\0
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H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
